Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan

Health Policy

Volumn 100, Issue 2-3, 2011, Pages 196-202

  Yeh, Hseng Long ^a,b   Huang, Li Ying ^c,d   Su, Syi ^d   Yang, Ming Chin ^d   Wang, Ting Chung ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; TAIWAN;

AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DATABASES AS TOPIC; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROTEINURIA; TAIWAN; VASOCONSTRICTOR AGENTS;

EID: 79954818123     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.11.010     Document Type: Article

References (27)

1. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine 1999, 341:1127-1133.
2. Bureau of National Health Insurance. About the program. Available from: http://www.nhi.gov.tw/english/index.asp?menu=&menu_id=30 [accessed 17.07.2010].
3. Bureau of National Health Insurance. National health insurance annual statistical report, 2000. Available at www.doh.gov.tw/statistic/index.htm. [accessed 30.06.2010].
4. Chang C.J., Lu F.H., Yang Y.C., Wu J.S., Wu T.J., Chen M.S., et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Research and Clinical Practice 2000, (Suppl. 2):S49-59.
5. Strippoli Giovanni F.M., Bonifati C., Craig Maria E., Navaneethan Sankar D., Craig Jonathan C. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, John Wiley & Sons, Ltd., Chichester, UK.
6. Investigators.HOPEHS Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
7. Winkelmayer W.C., Schneeweiss S., Mogun H., Patrick A.R., Avorn J., Solomon D.H. Identification of individuals with CKD from medicare claims data: a validation study. American Journal of Kidney Diseases 2005, 46(2):225-232.
8. Bennett H., Haffner S., Kasiske B.L., Keane W.F., Mogensen C.E., Parving H.-H., et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the scientific advisory board of the nationals Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. American Journal of Kidney Diseases 1995, 25:107-112.
9. American Diabetes Association Clinical Practice Recommendations. Diabetes Care 2004, 27:S1-150.
10. Winkelmayer W.C., Fischer M.A., Schneeweiss S., Wang P.S., Levin R., Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. American Journal of Kidney Diseases 2005, 46:1080-1087.
11. Chiang T.L. Taiwan's 1995 health care reform. Health Policy 1997, 39:225-239.
12. National Health Insurance Research Database, http://w3.nhri.org.tw/nhird//date_01.html [accessed 22.09 2010].
13. Huang Ping, Hsu Y.H., Tan K.Y., Hsush Y.S. Can European external peer review techniques be introduced and adopted into Taiwan's hospital accreditation system?. International Journal for Quality in Health Care 2000, 12:251-254.
14. Rosen A.B.K.A., Liu J.Y., Selby J.V., Schneider E.C. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. Journal of General Internal Medicine 2004, 19:669-675.
15. Liou H.H., Huang T.P., Campese V.M. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995, 69:41-48.
16. Matchar D.B., McCrory D.C., Orlando L.A., Patel M.R., Patel U.D., Patwardhan M.B., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Annals of Internal Medicine 2008, 148:16-29.
17. Fletcher A.E., Palmer A.J., Bulpitt C.J. Cough with angiotensin converting enzyme inhibitors: How much of a problem?. Journal of Hypertension 1994, 12(2):S43-S47.
18. Lindholm L.H., Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish trial in old patients with hypertension-2. Journal of Hypertension 2000, 18:1671-1675.
19. Winkelmayer W.C., Owen W.F., Levin R., Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. Journal of the American Society of Nephrology 2003, 14:486-492.
20. de Beaufort C.E., Reunanen A., Raleigh V., Storms F., Kleinebreil L., Gallego R., et al. European union diabetes indicators: fact or fiction?. European Journal of Public Health 2003, 13:51-54.
21. Voorham J., Haaijer-Ruskamp F.M., Stolk R.P., Wolffenbuttel B.H.R., Denig P. Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes. Diabetes Care 2008, 31:501-503.
22. Hartzema A.G., Tilson H.H., Chan K.A. Pharmacoepidemiology: and therapeutic risk management 2008, Harvey Whitney Books Co., Cincinnati, OH.
23. Guthrie B., Inkster M., Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. British Medical Journal 2007, 335:542-544.
24. Australian National Prescribing Service. Indicators of quality prescribing in Australian general practice; 2006. Available at http://www.nps.org.au/__data/assets/pdf_file/0019/37351/indicators_full.pdf [accessed 30.06.2010].
25. Lai Y.H., Hwang S.J., Yang W.C. National dialysis surveillance in Taiwan, Annual Report. Acta Nephrologica ROC 1998, 12:157-195.
26. Clark W.F., Churchill D.N., Forwell L., Macdonald G., Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting enzyme inhibitor therapy for diabetic nephropathy. Canadian Medical Association Journal 2000, 162:195-198.
27. Yang W.C., Hwang S.J., Chiang S.S., Chen H.F., Tsai S.T. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. Diabetes Research and Clinical Practice 2001, 54:47-54.